Examining the activity of cefepime-taniborbactam against Burkholderia cepacia complex and Burkholderia gladioli isolated from cystic fibrosis patients in the United States

被引：1
作者：
Mojica, Maria F. [1 ,2 ,3 ]
Zeiser, Elise T. [2 ]
Becka, Scott A. [2 ]
Lipuma, John J. [4 ]
Six, David A. [5 ]
Moeck, Greg [5 ]
Papp-Wallace, Krisztina M. [2 ,6 ,7 ]
机构：
[1] Case Western Reserve Univ, Dept Mol Biol & Microbiol, Cleveland, OH USA
[2] Vet Affairs Northeast Ohio Healthcare Syst, Res Serv, Cincinnati, OH 44106 USA
[3] CASE VA Ctr Antimicrobial Resistance & Epidemiol, Cleveland, OH 44106 USA
[4] Univ Michigan, Ann Arbor, MI USA
[5] Venatorx Pharmaceut Inc, Malyern, PA USA
[6] Case Western Reserve Univ, Dept Med, Cleveland, OH 44106 USA
[7] Case Western Reserve Univ, Dept Biochem, Cleveland, OH 44106 USA
来源：
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY | 2023年 / 67卷 / 11期
关键词：
beta-lactamases; Burkholderia; beta-lactam; PenA; carbapenemase; beta-lactamase inhibitor; cefepime-taniborbactam; BETA-LACTAMASES; RESISTANCE; CEFEPIME/TANIBORBACTAM; SUSCEPTIBILITY; COMBINATION; CEFTAZIDIME; PSEUDOMONAS; VNRX-5133;
D O I：
10.1128/aac.00498-23
中图分类号：
Q93 [微生物学];
学科分类号：
071005 ; 100705 ;
摘要：
The novel clinical-stage beta-lactam-beta-lactamase inhibitor combination, cefepime-taniborbactam, demonstrates promising activity toward many Gram-negative bacteria producing class A, B, C, and/or D beta-lactamases. We tested this combination against a panel of 150 Burkholderia cepacia complex (Bcc) and Burkholderia gladioli strains. The addition of taniborbactam to cefepime shifted cefepime minimum inhibitory concentrations toward the provisionally susceptible range in 59% of the isolates tested. Therefore, cefepime-taniborbactam possessed similar activity as first-line agents, ceftazidime and trimethoprim-sulfamethoxazole, supporting further development.
引用
收藏
页数：7
相关论文
共 35 条
  • [1] In vivo pharmacokinetic/pharmacodynamic evaluation of cefepime/taniborbactam combination against cefepime-non-susceptible Enterobacterales and Pseudomonas aeruginosa in a murine pneumonia model
    Abdelraouf, Kamilia
    Nicolau, David P.
    [J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2023, 78 (03) : 692 - 702
  • [2] In vivo pharmacodynamics of new-generation β-lactamase inhibitor taniborbactam (formerly VNRX-5133) in combination with cefepime against serine-β-lactamase-producing Gram-negative bacteria
    Abdelraouf, Kamilia
    Abuhussain, Safa Almarzoky
    Nicolau, David P.
    [J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2020, 75 (12) : 3601 - 3610
  • [3] Activity of Imipenem-Relebactam against Multidrug- and Extensively Drug-Resistant Burkholderia cepacia Complex and Burkholderia gladioli
    Becka, Scott A.
    Zeiser, Elise T.
    LiPuma, John J.
    Papp-Wallace, Krisztina M.
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2021, 65 (11)
  • [4] Characterization of the AmpC β-Lactamase from Burkholderia multivorans
    Becka, Scott A.
    Zeiser, Elise T.
    Barnes, Melissa D.
    Taracila, Magdalena A.
    Nguyen, Kevin
    Singh, Indresh
    Sutton, Granger G.
    LiPuma, John J.
    Fouts, Derrick E.
    Papp-Wallace, Krisztina M.
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2018, 62 (10)
  • [5] Sequence heterogeneity of the PenA carbapenemase in clinical isolates of Burkholderia multivorans
    Becka, Scott A.
    Zeiser, Elise T.
    Marshall, Steven H.
    Gatta, Julian A.
    Nguyen, Kevin
    Singh, Indresh
    Greco, Chris
    Sutton, Granger G.
    Fouts, Derrick E.
    LiPuma, John J.
    Papp-Wallace, Krisztina M.
    [J]. DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 2018, 92 (03) : 253 - 258
  • [6] Microbiology of Cystic Fibrosis Airway Disease
    Blanchard, Ana C.
    Waters, Valerie J.
    [J]. SEMINARS IN RESPIRATORY AND CRITICAL CARE MEDICINE, 2019, 40 (06) : 727 - 736
  • [7] A FUNCTIONAL CLASSIFICATION SCHEME FOR BETA-LACTAMASES AND ITS CORRELATION WITH MOLECULAR-STRUCTURE
    BUSH, K
    JACOBY, GA
    MEDEIROS, AA
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1995, 39 (06) : 1211 - 1233
  • [8] CaLSI, 2021, Performance standards for antimicrobial susceptibility testing, V31st
  • [9] Antimicrobial resistance to ceftazidime involving loss of penicillin-binding protein 3 in Burkholderia pseudomallei
    Chantratita, Narisara
    Rholl, Drew A.
    Sim, Bernice
    Wuthiekanun, Vanaporn
    Limmathurotsakul, Direk
    Amornchai, Premjit
    Thanwisai, Aunchalee
    Chua, Hui Hoon
    Ooi, Wen Fong
    Holden, Matthew T. G.
    Day, Nicholas P.
    Tan, Patrick
    Schweizer, Herbert P.
    Peacock, Sharon J.
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2011, 108 (41) : 17165 - 17170
  • [10] Safety and Pharmacokinetics of Taniborbactam (VNRX-5133) with Cefepime in Subjects with Various Degrees of Renal Impairment
    Dowell, James A.
    Marbury, Thomas C.
    Smith, William B.
    Henkel, Tim
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2022, 66 (09)
1234